Member Info for magmanus_49

still holding here. buy and hold. JB did not get through, buy who cares. He payed it all wrong, hoping the cliams have stablised or mayeba few more due to covid related issues. in the end wil be fine.

excellent entry at 12p. well don if you buyig and holding.

following on from Thursdays transformational transaction we have 4 milestones to look forward to this month. 1)Regulator approvals 2)Underwriter approvals 3)SPA documentation 4)Execution of SPA ... expecting SP to continue to build as the month progresses

tr1 first - egmos need to get out...

onwards and upwards - over 0.1p - just show me the tr1's please.

Just need the warranst done this week - with news it will still be held back. So i expect EGMOS to clear this week - before news. Their range is 0.011 to 0.015 to clear - as noted over the last few weeks. Looking for the TR1 tomorrow or Tuesday to see their holding left. They were busy selling last week - about 2-3b offloaded last week.

my order n5.60+. wr should break through 8p soon - as part of accummulation process.

need RGMOS out before JM update. If ot then buying more when we have TR1 from EGMOS - has enough of them - idiots destryoing shareholder value - after knowing ICON make big strides. I am waiting on their TR1 towars 0% to buy more. either way. Management will let them out, as EGMOS has announced they are selling the warrnats since 6th Oct. Not holding.

this week- JM news update will announced once contract is signed with ICON. So may be another week yet as EGHOS selles off. buy/hold always. :)

of the their eye drug very soon - that could be next news pending - which will be send the s soaring over 30p - as this market is multi-billion dollar and OKYO is right at the center.

we will have great week here. imho.

Dr. Napoleone Ferrara stated: “I am delighted to join OKYO Pharma as a member of the SAB. OKYO’s focus on the development of long-acting GPCR agonists to treat dry eye and ocular pain is scientifically sound and promising. GPCRs are key targets for pharmacological intervention in a variety of diseases. My expertise in ocular angiogenesis should complement these efforts and I look forward to an exciting collaboration”.

Willy Simon, Chairman of OKYO said: “We are very excited about Dr. Napoleone Ferrara’s addition to the OKYO team. Very few scientists have invented two different blockbuster drugs such as Avastin® and Lucentis®. Lucentis® has become one of the major blockbuster drugs to treat eye disease and Napoleone’s experience will be a huge value added to Okyo’s drug development effort.”

Dr. Napoleone Ferrara’s has also commercilaised simliar drugs - in this multi-billion dollar market.

So what is next.....

Dr. James Khodabakhsh specializes in complex surgeries of the eye and is one of the most sought after surgeons in Los Angeles and is the Medical Director at the Beverly Hills Institute of Ophthalmology.

Dr. Khodabakhsh has performed over 40,000 eye surgical procedures including LASIK, Glaucoma and cataract surgeries. Dr. Khodabakhsh is also presently the Chief and Chairman of the Department of Ophthalmology at the Cedars Sinai Medical Centre where he is involved in multiple Clinical trials.

“I’m honored to lead the SAB board of Okyo pharmaceuticals. I’m looking forward to building a first class team and accelerate the clinical development of our compounds for the treatment of dry eyes and inflammation. This space has tremendous potential for growth and I truly feel we can add to it with our molecules,” said Dr. Khodabakhsh.

Willy Simon, Chairman of OKYO said: "It gives me great pleasure to have Dr. Khodabakhsh leading and chairing the new Scientific Advisory Board and I am honoured that he considers the Company's clinical pipeline to be of clinical interest in the context of his treating patients in the field. We look forward to fully utilising his deep experience and clinical knowledge to assist in driving the development of Chemerin to its nest stages of development."

In addtion to SPA in 30 days, also expect BKM Copper Project update - final approvals - at anytime. On BKM approval/ final signatures i fully expect pps to be 14p+. Libirium will up its current target from 14p to 20p in good time. Multi- bagger here. Monday gap and over 6p, as it moves to arpund 8p as next stop.

This huge £125m deal, for Asiamet - which is now unlocking huge value for shareholders.

Asiamet Resources Limited ("Asiamet" or the "Company") is pleased to announce it has entered into a non-binding Heads of Agreement ("HoA") with PT Wasesa Indo Nusa ("PT WIN"), an Indonesian private company, to acquire Asiamet's wholly-owned subsidiary Indokal Limited ("Indokal") (the "Proposed Transaction"). Indokal holds the Kalimantan Surya Kencana Contract of Work ("KSK CoW"), including the BKM Copper Project, located in Central Kalimantan, Indonesia.

As part of the Proposed Transaction, PT WIN will also acquire Aeturnum Energy International PTE Limited's ("Aeturnum") commodities trading business. PT WIN plans to undertake an Initial Public Offering ("IPO") on the Indonesian Stock Exchange ("IDX") in early 2021. Discussions are currently underway with several highly rated Indonesian financial institutions to underwrite the IPO. With its existing cash reserves and expected proceeds from the planned IPO, PT WIN expects to have sufficient financial resources to enable the development pathway for the BKM Copper Project.

"The Asiamet Board fully endorses and supports this transaction. While it is recognised that there are still a number of steps to completion, the proposed transaction has the potential to unlock very significant unrecognised value for Asiamet shareholders and most importantly secures a clear road map for the funding and development of the BKM copper project and the further advancement of the wider KSK CoW for the benefit of all stakeholders. Asiamet will retain a very meaningful exposure to the upside at BKM and KSK and continue to manage all the value enhancement and development related activities currently in progress.

Our work with Aeturnum to date has provided an insight into their high level of professionalism and integrity and provided us with the confidence to pursue this transaction and partner with them as major shareholders in the proposed IDX listing and development of PT WIN going forward. We now remain focused on completing due diligence and binding documentation that allows for shareholder approval."

Pecten - I have thigs to say and share my research - you do nothing much - i bet you sold today - if you ever bought in the first place. Don't see the posts of likes of you etc.

Anyway, today was consilidation day following yesterday suprise news - lon awaited mind you - - which was good to see. expect a big day next week to re-rate to 8+. and it should hold aroudn 10p min - as further updates are now expected. Significant shareholder value - as explained by CEO yesterday, and what we can see upcomming. If youw ant multi-bagger - show me the money - its right here. period.

have nice weekend

hitman - so broker note of 14p is too low? should it be 21p - based on £135m cash deal. And how much woudl you value their other major assets? 6p or 1p?????????
nobody is ramping here. just buying the house here.

pectan11 - yes. now bye.

ask was 5..05 mins before close - until a few sold as friday/ we. good sellers remorse will set in soon enough here.

excellet closeon a friday, surely will gap on monday and be over 6p. mice and easy. many wil need to nuy back after selling end of day today. Madness to sell, when we have broker target of 14p now, and £165m cash coming ARS's way. have great week. more major news to follow. Easy multi bagger from here. very stromg close, admist alot of selling - easily done by by mms.

on a friday....! looks liek will rocket on Monday and next week.